EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Dayang Wang, Jiubing Zhang, Chaojie Bu, Guanzheng Liu, Guangzhong Guo, Ziyue Zhang, Guangming Lv, Zhiyuan Sheng, Zhaoyue Yan, Yvshuai Gao, Meiyun Wang, Gang Liu und 4 weitere

Journal of Cancer Research and Clinical Oncology · 18.10.2024 · 150 (10)

DOI: 10.1007/s00432-024-05997-8 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 18.10.2024. Verfasst von Dayang Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Brain Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Henan Province, Research Foundation of the National Health Commission of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Immune checkpoint blockade (ICB) therapies have shown efficacy in various tumors, but long-term responses in glioblastoma are less than 10%. Quantifying tumor in situ fluid circulating tumor DNA (TISF-ctDNA) and therapeutic dynamics may enable real-time GBM disease burden evaluation. This study explores the potential of tumor in situ fluid circulating tumor DNA (TISF-ctDNA) dynamics in predicting treatment efficacy. METHODS: TISF and peripheral blood samples were collected from patients with recurrent glioblastoma (rGBM) undergoing tislelizumab (a programmed death 1 inhibitor) combined with low-dose bevacizumab (an anti-vascular endothelial growth factor antibody) treatment before and during each immunotherapy cycle. Biomarkers evaluated included TISF-ctDNA, measured using Next Generation Sequencing (NGS), and host inflammation markers such as the platelet-to-lymphocyte ratio (PLR). RESULTS: All 32 patients received tislelizumab plus low-dose bevacizumab regularly. The median progression-free survival (PFS) was 4.0 months, and overall survival (OS) was 22.3 months. An analysis of 19 patients with continuous evaluable TISF showed baseline TISF-ctDNA abundance did not correlate with OS (p = 0.23) or PFS (p = 0.23). However, a change in TISF-ctDNA maximal Somatic Variant Allelic Frequency (MVAF) after six treatment cycles predicted both PFS (p = 0.02) and OS (p < 0.0001). Lower baseline PLR also correlated with better survival outcomes. CONCLUSION: The combination of tislelizumab and low-dose bevacizumab therapy appears to be effective in extending both OS and PFS in rGBM patients. Continuous TISF-ctDNA testing shows potential utility in complementing radiological monitoring. The temporal change pattern of TISF MVAF is more predictive of immunotherapy response than imaging. PLR before immunotherapy can screen patients likely to benefit from tislelizumab plus low-dose bevacizumab therapy. TRIAL REGISTRATION: The trial registration number: NCT05502991; Date of registration: 2022-08-14.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain NeoplasmsCirculating Tumor DNAGlioblastomaImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedBiomarkers, TumorTreatment Outcome

Stichwörter der Autor:innen

Circulating tumor DNAImmune checkpoint blockadeRecurrent glioblastomaTumor in situ fluid

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumabBiomarkers, TumorCirculating Tumor DNAImmune Checkpoint Inhibitorstislelizumab

Autor:innen und Institutionen

  • Department of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
  • Precision Diagnosis and Treatment Engineering Research Center for Glioma Henan Province, Zhengzhou, China.
  • Clinical Center for Glioma Henan Provincial People's Hospital, Zhengzhou, China.
  • Department of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
  • Department of Psychological Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Department of Radiology, Henan Provincial People's Hospital, Zhengzhou, China.

Förderung

  • Natural Science Foundation of Henan Province
  • Research Foundation of the National Health Commission of China

Zitieren

APA

Wang, D., Zhang, J., Bu, C., Liu, G., Guo, G., Zhang, Z., Lv, G., Sheng, Z., Yan, Z., Gao, Y., Wang, M., Liu, G., Zhao, R., Li, T., Ma, C., & Bu, X. (2024). Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab. Journal of Cancer Research and Clinical Oncology, 150(10). https://doi.org/10.1007/s00432-024-05997-8

Vancouver

Wang D, Zhang J, Bu C, Liu G, Guo G, Zhang Z, et al. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab. Journal of Cancer Research and Clinical Oncology. 2024;150(10). doi:10.1007/s00432-024-05997-8

BibTeX
@article{Wang2024,
  author = {Wang, Dayang and Zhang, Jiubing and Bu, Chaojie and Liu, Guanzheng and Guo, Guangzhong and Zhang, Ziyue and Lv, Guangming and Sheng, Zhiyuan and Yan, Zhaoyue and Gao, Yvshuai and Wang, Meiyun and Liu, Gang and Zhao, Ruijiao and Li, Tianxiao and Ma, Chunxiao and Bu, Xingyao},
  title = {Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {10},
  doi = {10.1007/s00432-024-05997-8}
}
Kostenlos starten →